Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS (GENIL) - Total Assets
Based on the latest financial reports, Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS (GENIL) holds total assets worth TL17.28 Billion TRY (≈ $387.06 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Gen Ilac ve Saglik Urunleri Sanayi ve Ti debt service capacity to assess how comfortably operating cash covers total debt obligations.
Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS - Total Assets Trend (2018–2024)
This chart illustrates how Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS's total assets have evolved over time, based on quarterly financial data. See GENIL net asset value for net asset value and shareholders' equity analysis.
Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS - Asset Composition Analysis
Current Asset Composition (December 2024)
Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS's total assets of TL17.28 Billion consist of 47.1% current assets and 52.9% non-current assets.
| Asset Category | Amount (TRY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | TL0.00 | 4.4% |
| Accounts Receivable | TL1.64 Billion | 13.3% |
| Inventory | TL1.07 Billion | 8.7% |
| Property, Plant & Equipment | TL0.00 | 0.0% |
| Intangible Assets | TL963.44 Million | 7.8% |
| Goodwill | TL0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Gen Ilac ve Saglik Urunleri Sanayi ve Ti market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS's current assets represent 47.1% of total assets in 2024, a decrease from 64.7% in 2018.
- Cash Position: Cash and equivalents constituted 4.4% of total assets in 2024, up from 1.4% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 7.0% of total assets, an increase from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 13.3% of total assets.
Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS Competitors by Total Assets
Key competitors of Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Shanghai Haoyuan Chemexpress Co. Ltd. A
SHG:688131
|
China | CN¥6.49 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099
|
China | CN¥7.28 Billion |
|
Celltrion Pharm Inc
KQ:068760
|
Korea | ₩745.80 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Heilongjiang ZBD Pharmaceutical Co Ltd
SHG:603567
|
China | CN¥11.80 Billion |
|
Zhejiang Anglikang Pharmaceutical Co Ltd Class A
SHE:002940
|
China | CN¥3.12 Billion |
Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.35 | 1.56 | 2.43 |
| Quick Ratio | 1.06 | 1.24 | 1.95 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | TL2.22 Billion | TL1.74 Billion | TL827.43 Million |
Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS - Advanced Valuation Insights
This section examines the relationship between Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.72 |
| Latest Market Cap to Assets Ratio | 0.08 |
| Asset Growth Rate (YoY) | 10.6% |
| Total Assets | TL12.31 Billion |
| Market Capitalization | $939.35 Million USD |
Valuation Analysis
Below Book Valuation: The market values Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS's assets below their book value (0.08x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS's assets grew by 10.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS (2018–2024)
The table below shows the annual total assets of Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | TL12.31 Billion ≈ $275.73 Million |
+10.56% |
| 2023-12-31 | TL11.13 Billion ≈ $249.39 Million |
+202.38% |
| 2022-12-31 | TL3.68 Billion ≈ $82.48 Million |
+73.75% |
| 2021-12-31 | TL2.12 Billion ≈ $47.47 Million |
+96.56% |
| 2020-12-31 | TL1.08 Billion ≈ $24.15 Million |
+92.46% |
| 2019-12-31 | TL560.23 Million ≈ $12.55 Million |
+35.78% |
| 2018-12-31 | TL412.62 Million ≈ $9.24 Million |
-- |
About Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS
Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi, a pharmaceutical company, manufactures and supplies products to treat rare diseases and disorders worldwide. The company offers its products in various areas, such as neurology, endocrinology, nephrology, oncology, hematology, and pediatric. Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi has collaboration with Sulfateq BV… Read more